Exchange and Ticker: Nasdaq: ARYX
Filing Range: 5M shares @ $14.00 to $16.00
Offering Price: $10.00
Close on First Day: $9.00
Offering Size: $50.00M
Shares Outstanding: 17,536,645
Underwriters: Morgan Stanley
CoManager: CIBC WorldMarkets Inc./ Jefferies & Co. Inc./ Leerink Swann & Co.
Company Counsel: Cooley Godward
Manager Counsel: Davis Polk & Wardwell
Auditor: Ernst & Young LLP
Market Capitalization on 11/30/07: $131.52M
Close price at current month end: $7.50
Company aims to enhance drug safety using the retro-metabolic concept. Its products are conceived around validated targets, using therapeutic agents. This method is designed to produce inherently safer drugs, addressing a medical need of the pharmaceutical industry. Competitors include Novartis Pharmaceuticals Corp., Alizyme plc, Johnson & Johnson, Bayer AG, Pfizer Inc. and Eli Lilly.
Ascent Biomedical Ventures, ATEL Ventures Inc., Itochu Corp., JAFCO Co., JAFCO Investment, Merlin Nexus, Montreux Equity Partners, MPM Capital, OrbiMed Advisors.
Source: Thomson Financial